Heterogeneous reduction of myocardial oxidative metabolism in patients with ischemic and dilated cardiomyopathy using C-11 acetate PET

Circulation Journal

Volumn 72, Issue 5, 2008, Pages 786-792

  Wu, Yen Wen ^a   Naya, Masanao ^b   Tsukamoto, Takahiro ^b   Komatsu, Hiroshi ^b   Morita, Koichi ^b   Yoshinaga, Keiichiro ^b   Kuge, Yuji ^b   Tsutsui, Hiroyuki ^b   Tamaki, Nagara ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbon 11 acetate PET; Dilated cardiomyopathy; Ischemic cardiomyopathy; Left ventricular dysfunction; Myocardial oxidative metabolism

Indexed keywords

ACETIC ACID C 11;

ADULT; AEROBIC METABOLISM; ARTICLE; CARDIOMYOPATHY; CLEARANCE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HUMAN; HUMAN TISSUE; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; STATISTICAL SIGNIFICANCE;

ACETATES; AGED; BUNDLE-BRANCH BLOCK; CARBON RADIOISOTOPES; CARDIOMYOPATHY, DILATED; ENERGY METABOLISM; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS;

EID: 44149102888     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.786     Document Type: Article

References (54)

1. Huss JM, Kelly D. Mitochondrial energy metabolism in heart failure: A question of balance. J Clin Invest 2005; 115: 547-555.
2. Klein LJ, Visser FC, Knaapen P, Peters JH, Teule GJ, Visser CA, et al. Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med 2001; 28: 651-668.
3. Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 1987; 76: 687-696.
4. Buxton DB, Nienaber CA, Luxen A, Ratib O, Hansen H, Phelps ME, et al. Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1-11C] acetate dynamic positron emission tomography. Circulation 1989; 79: 134-142.
5. Gropler RJ, Siegel BA, Sampathkumaran K, Perez JE, Schechtman KB, Conversano A, et al. Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol 1992; 9: 989-997.
6. Tamaki N, Magata Y, Takahashi N, Kawamoto M, Torizuka T, Yonekura Y, et at. Oxidative metabolism in the myocardium in normal subjects during dobutamine infusion. Eur J Nucl Med 1993; 20: 231-237.
7. Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993; 22: 1389-1398.
8. Kalff V, Hicks RJ, Hutchins G, Topol E, Schwaiger M. Use of carbon-11 acetate and dynamic positron emission tomography to assess regional myocardial oxygen consumption in patients with acute myocardial infarction receiving thrombolysis or coronary angioplasty. Am J Cardiol 1993; 71: 529-535.
9. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate: Comparison between the normal and failing human heart. Eur J Nucl Med 2000; 27: 319-326.
10. Imanishi R, Seto S, Ichimaru S, Nakashima E, Yano K, Akahoshi M. Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J Cardiol 2006; 98: 644-648.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
12. Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1-11C]acetate: An agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot 1982; 33: 505-512.
13. Torizuka T, Tamaki N, Kasagi K, Misaki T, Kawamoto M, Tadamura E, et al. Myocardial oxidative metabolism in hyperthyroid patients assessed by PET with carbon-11-acetate. J Nucl Med 1995; 36: 1981-1986.
14. 11C-acetate in patients with old myocardial infarction: Usefulness of low-dose dobutamine infusion. Circulation 1996; 94: 1834-1841.
15. Yoshinaga K, Katoh C, Beanlands RS, Noriyasu K, Komuro K, Yamada S, et al. Reduced oxidative metabolic response in dysfunctional myocardium with preserved glucose metabolism but with impaired contractile reserve. J Nucl Med 2004; 45: 1885-1891.
16. Gropler RJ, Siegel BA, Geltman EM. Myocardial uptake of carbon-11-acetate as an indirect estimate myocardial blood flow. J Nucl Med 1991; 32: 245-251.
17. Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic and hyperemic canine myocardium. Circulation 1990; 81: 1594-1605.
18. Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000; 102: 2070-2075.
19. Chikamori T, Doi YL, Yonezewa Y, Yamada M, Seo H, Ozawa T. Values of dipyridamole thallium-201 imaging in noninvasive differentiation of idiopathic dilated cardiomyopathy from coronary artery disease with left ventricular dysfunction. Am J Cardiol 1992; 69: 650-653.
20. Mody FV, Brunken RC, Stevenson LW, Nienaber CA, Phelps ME, Schelbert HR. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography. J Am Coll Cardiol 1991; 17: 373-383.
21. Danias PG, Papaioannou GI, Ahlberg AW, O'Sullivan DM, Mann A, Boden WE, et al. Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. Am J Cardiol 2004; 94: 14-19.
22. Marini C, Giorgetti A, Gimelli A, Kusch A, Sereni N, L'abbate A, et al. Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 2005; 32: 682-688.
23. Di Carli MF, Prcevski P, Singh TP, Janisse J, Ager J, Muzik O, et al. Myocardial blood flow, function, and metabolism in repetitive stunning. J Nucl Med 2000; 41: 1227-1234.
24. Ohte N, Kurokawa K, Iida A, Narita H, Akita S, Yajima K, et al. Myocardial oxidative metabolism in remote normal regions in the left ventricles with remodeling after myocardial infarction: Effect of β-adrenoreceptor blockers. J Nucl Med 2002; 43: 780-785.
25. Bach DS, Beanlands RS, Schwaiger M, Armstrong WF. Heterogeneity of ventricular function and myocardial and myocardial oxidative metabolism in nonischemic dilated cardiomyopathy. J Am Coll Cardiol 1995; 25: 1258-1262.
26. Tuunanen H, Kuusisto J, Toikka J, Jaaskelainen P, Marjamaki P, Peuhkurinen K, et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: A positron emission tomography study. J Nucl Cardiol 2007; 14: 354-365.
27. Lindner O, Vogt J, Baller D, Kammeier A, Wielepp P, Holzinger J, et al. Global and regional myocardial oxygen consumption and blood flow in severe cardiomyopathy with left bundle branch block. Eur J Heart Fail 2005; 7: 225-230.
28. Wu YW, Yen RF, Chieng PU, Huang PJ. Thallium-201 myocardial perfusion imaging in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol 2003; 10: 369-374.
29. O'Neill JO, McCarthy PM, Brunken RC, Buda T, Hoercher K, Young JB, et al. PET abnormalities in patients with nonischemic cardiomyopathy. J Cardiol Fail 2004; 10: 244-249.
30. Knaapen P, Gotte MJ, Paulus WJ, Zwanenburg JJ, Dijkmans PA, Boellaard R, et al. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy?: PET and MR imaging study. Radiology 2006; 240: 380-388.
31. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, et al. Endothelium- dependent dilatation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990; 83: 772-779.
32. Juilliere Y, Marie PY, Danchin N, Gillet C, Paille F, Karcher G, et al. Radionuclide assessment of regional difference in left ventricular wall motion and myocardial perfusion in idiopathic dilated cardiomyopathy. Eur Heart J 1993; 14: 1163-1169.
33. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000; 35: 19-28.
34. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984; 54: 147-152.
35. Sugihara H, Tamaki N, Nozawa M, Ohmura T, Inamoto Y, Taniguchi Y, et al. Septal perfusion and wall thickening in patients with left bundle branch block assessed by technetium-99m-sestamibi gated tomography. J Nucl Med 1997; 38: 545-547.
36. Ono S, Nohara R, Kambara H, Okuda K, Kawai C. Regional myocardial perfusion and glucose metabolism in experimental left bundle branch block. Circulation 1992; 85: 1125-1131.
37. Nowak B, Stellbrink C, Schaefer WM, Sinha AM, Breithardt OA, Kaiser HJ, et al. Comparison of regional myocardial blood flow and perfusion in dilated cardiomyopathy and left bundle branch: Role of wall thickening. J Nucl Med 2004; 45: 414-418.
38. Zanco P, Desideri A, Mobilia G, Cargnel S, Milan E, Celegon L, et al. Effects of left bundle branch block on myocardial FDG PET in patients without significant coronary artery stenoses. J Nucl Med 2000; 41: 973-977.
39. Altehoefer C, vom Dahl J, Bares R, Stocklin GL, Bull U. Metabolic mismatch of septal beta-oxidation and glucose utilization in left bundle branch block assessed with PET. J Nucl Med 1995; 36: 2056-2059.
40. Vernooy K, Verbeek XA, Peschar M, Crijns HJ, Arts T, Cornelussen RN, et al. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J 2005; 26: 91-98.
41. 15O-water PET. Circ J 2007; 71: 884-890.
42. Inoue N, Takahashi N, Ishikawa T, Sumita S, Kobayashi T, Matsushita K, et al. Reverse perfusion-metabolism mismatch predicts good prognosis in patients undergoing cardiac resynchronization therapy: A pilot study. Circ J 2007; 71: 126-131.
43. Fantoni C, Kawabata M, Massaro R, Regoli F, Raffa S, Arora V, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: A detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 2005; 16: 112-119.
44. Nowak B, Sinha AM, Schaefer WM, Koch KC, Kaiser HJ, Hanrath P, et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2003; 41: 1523-1528.
45. Knaapen P, van Campen LM, de Cock CC, Gotte MJ, Visser CA, Lammertsma AA, et al. Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation 2004; 110: 646-651.
46. Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation 2003; 107: 28-31.
47. Sundell J, Engblom E, Koistinen J, Ylitalo A, Naum A, Stolen KQ, et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2004; 43: 1027-1033.
48. Lindner O, Vogt J, Kammeier A, Wielepp P, Holzinger J, Baller D, et al. Effect of cardiac resynchronization therapy on global and regional oxygen consumption and myocardial blood flow in patients with non-ischemic and ischemic cardiomyopathy. Eur Heart J 2005; 26: 70-76.
49. 11C-acetate PET after long-term cardiac resynchronization therapy. J Nucl Med 2006; 47: 373-383.
50. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation: Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
51. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, et al; Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-2033.
52. Knuesel PR, Nanz D, Wyss C, Buechi M, Kaufmann PA, von Schulthess GK, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: Relation to functional outcome after revascularization. Circulation 2003; 108: 1095-1100.
53. 201Tl-SPECT in dysfunctional myocardium: Relation to early functional outcome after surgical revascularization in chronic ischemic heart disease. J Nucl Med 2007; 48: 1096-1103.
54. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG, et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003; 41: 293-299.